Microbiome pioneer Seres crushed as lead drug flops in PhII
One of the pioneers in the microbiome R&D world has slammed into a Phase II failure for its lead program. Seres Therapeutics $MCRB says …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
